Doris Quinkert
Overview
Explore the profile of Doris Quinkert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrison T, Alam N, Farrell B, Quinkert D, Lias A, King L, et al.
EMBO Mol Med
. 2024 Sep;
16(10):2539-2559.
PMID: 39223355
There is an urgent need for improved malaria vaccine immunogens. Invasion of erythrocytes by Plasmodium falciparum is essential for its life cycle, preceding symptoms of disease and parasite transmission. Antibodies...
2.
Barrett J, Pipini D, Wright N, Cooper A, Gorini G, Quinkert D, et al.
Cell
. 2024 Jul;
187(18):4964-4980.e21.
PMID: 39059380
The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features...
3.
King L, Pulido D, Barrett J, Davies H, Quinkert D, Lias A, et al.
Cell Rep Med
. 2024 Jul;
5(7):101654.
PMID: 39019011
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called...
4.
Williams B, King L, Pulido D, Quinkert D, Lias A, Silk S, et al.
Nat Commun
. 2024 Jun;
15(1):4857.
PMID: 38849365
Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric "RCR-complex". We...
5.
Segireddy R, Belda H, Yang A, Dundas K, Knoeckel J, Galaway F, et al.
Malar J
. 2024 May;
23(1):151.
PMID: 38755636
Background: Sporozoite invasion of hepatocytes is an essential step in the Plasmodium life-cycle and has similarities, at the cellular level, to merozoite invasion of erythrocytes. In the case of the...
6.
Mertens J, Rigby C, Bardelli M, Quinkert D, Hou M, Diouf A, et al.
Vaccine
. 2024 May;
42(16):3621-3629.
PMID: 38704253
Recent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth...
7.
Weiss G, Ragotte R, Quinkert D, Lias A, Dans M, Boulet C, et al.
PLoS Pathog
. 2023 Sep;
19(9):e1011182.
PMID: 37713419
The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the current leading blood-stage malaria vaccine candidate. PfRH5 functions as part of the pentameric PCRCR complex containing PTRAMP, CSS, PfCyRPA and...
8.
Salkeld J, Themistocleous Y, Barrett J, Mitton C, Rawlinson T, Payne R, et al.
Front Immunol
. 2022 Sep;
13:984323.
PMID: 36072606
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03906474, NCT02927145.
9.
Nacer A, Kivi G, Pert R, Juronen E, Holenya P, Aliprandini E, et al.
Front Cell Infect Microbiol
. 2022 Jul;
12:901253.
PMID: 35782147
Malaria, an infection caused by apicomplexan parasites of the genus , continues to exact a significant toll on public health with over 200 million cases world-wide, and annual deaths in...
10.
Ragotte R, Pulido D, Lias A, Quinkert D, Alanine D, Jamwal A, et al.
Nat Commun
. 2022 Feb;
13(1):933.
PMID: 35177602
Understanding mechanisms of antibody synergy is important for vaccine design and antibody cocktail development. Examples of synergy between antibodies are well-documented, but the mechanisms underlying these relationships often remain poorly...